Summary: A proven track record of putting shareholders first is part of the litmus test
Summary: AbbVie Inc.’s revenue growth has turned negative due to the expiration of Humira patents,
Summary: Despite his reputation as a growth investor, Peter Lynch offers valuable insights into dividend
Summary: AbbVie’s management increased the financial guidance for its 2023 adjusted diluted EPS from $10.86–$11.06
Summary: AbbVie’s Q3 earnings will be announced on October 27th. This blue chip pharma offers
Summary: The US FDA has already approved two directly interchangeable biosimilars to ABBV’s Humira, namely
Summary: AbbVie is a leading pharmaceutical company with a strong history and a diverse portfolio
Summary: Dividend Kings are the most battle-tested dividend payers on Wall Street, with AbbVie being
Summary: AbbVie is expected to report a decline in EPS and revenue for Q3 2023,
Summary: Since its spin-off from Abbott Labs, AbbVie has delivered outstanding performance, surpassing both its